Connect your AI

Evolus EOLS Stock-Based Comp

Stock-Based Comp at other companies

AbbVieABBV

$444M+8.3%

Other financials

Income statement

Revenue$73.1M+6.7%

Gross profit$48.9M+4.8%

Operating income-$6.8M+54.9%

Net income-$10.7M+43.5%

EPS (diluted)-$0.16+46.7%

Balance sheet

Cash & equivalents$49.8M-26.7%

Total debt$164.9M-4.1%

Total equity-$28.8M-336%

Total assets$220.6M+3.4%

Cash flow

Operating cash flow-$10.0M+36.3%

CapEx$415.0K+30.1%

Free cash flow-$10.4M+35.0%

Valuation

Market cap$470.86M-21.3%

Enterprise value$585.97M-16.6%

P/S1.6×-0.6×

Profitability

Gross margin66.1%-2.4pp

Operating margin-13.7%-1.9pp

Net margin-14.4%-3.3pp

FCF margin-9.6%-3.6pp

Returns & leverage

Return on equity-472.6%-1,534pp

Debt / equity22.2×—

Current ratio2×-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evolus's stock-based comp?: Evolus (EOLS) reported stock-based comp of $5.12M in Q1 2026.
How has Evolus's stock-based comp changed year-over-year?: Evolus's stock-based comp decreased by 13.7% year-over-year, from $5.93M to $5.12M.
What is the long-term trend for Evolus's stock-based comp?: Over 4 years (2021 to 2025), Evolus's stock-based comp has grown at a 21.3% compound annual growth rate (CAGR), from $9.58M to $20.7M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.